KEGG   DISEASE: Ovarian cancer
H00027                      Disease                                

Ovarian cancer
Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.
Human diseases [BR:br08402]
  Cancers of the breast and female genital organs
   H00027  Ovarian cancer
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  Malignant neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of female genital organs
     2C73  Malignant neoplasms of ovary
      H00027  Ovarian cancer
Tumor markers [br08442.html]
Cancer-associated carbohydrates [br08441.html]
hsa05206  MicroRNAs in cancer
BRCA1 (germline mutation / deletion) [HSA:672] [KO:K10605]
BRCA2 (germline mutation / deletion) [HSA:675] [KO:K08775]
MSH2 (germline mutation) [HSA:4436] [KO:K08735]
MLH1 (germline mutation) [HSA:4292] [KO:K08734]
ERBB2 (amplification / overexpression) [HSA:2064] [KO:K05083]
K-ras (mutation) [HSA:3845] [KO:K07827]
AKT2 (amplification) [HSA:208] [KO:K04456]
PIK3CA (amplification) [HSA:5290] [KO:K00922]
c-MYC (overexpression) [HSA:4609] [KO:K04377]
p53 (mutation / deletion, overexpression) [HSA:7157] [KO:K04451]
Cyclophosphamide [DR:D00287]
Melphalan [DR:D00369]
Thiotepa [DR:D00583]
Gemcitabine hydrochloride [DR:D01155]
Paclitaxel [DR:D00491]
Doxorubicin hydrochloride [DR:D01275]
Cisplatin [DR:D00275]
Carboplatin [DR:D01363]
Bevacizumab [DR:D06409]
Altretamine [DR:D02841]
Topotecan hydrochloride [DR:D02168]
Olaparib [DR:D09730] (HRD-positive)
Niraparib tosilate hydrate [DR:D11895]
Rucaparib camsylate [DR:D10982] (BRCA-mutated)
ICD-O: 8441/3, Tumor type: Adenocarcinoma
ICD-O: 8480/3, Tumor type: Adenocarcinoma
ICD-O: 8380/3, Tumor type: Adenocarcinoma, not otherwise specified
ICD-O: 8310/3, Tumor type: Adenocarcinoma
ICD-O: 9000/3, Tumor type: Malignant Brenner tumor
Other DBs
ICD-11: 2C73
ICD-10: C56
MeSH: D010051
PMID:15111296 (tumor type)
Shih IeM, Kurman RJ.
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
Am J Pathol 164:1511-8 (2004)
PMID:12886939 (gene, tumor type)
Katabuchi H, Okamura H.
Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis.
Med Electron Microsc 36:74-86 (2003)
Wenham RM, Lancaster JM, Berchuck A.
Molecular aspects of ovarian cancer.
Best Pract Res Clin Obstet Gynaecol 16:483-97 (2002)

» Japanese version

DBGET integrated database retrieval system